Importantly, our results suggest that ANXA13 enhances tumor cell invasion through activation of the AKT-MMP-9 pathway, since the AKT inhibitor LY29004 abolished ANXA13-enhanced tumor cell invasion. This evidence concerns the gene AKT1 and neoplasm.